RBC Capital Markets analyst Brian Abrahams suggested that AveXis could indirectly benefit from payment arrangements made by Spark Therapeutics for the gene therapy Luxturna, MarketWatch reported Wednesday.
AveXis reported positive early-stage study results for its investigational gene therapy AVXS-101 in November last year.
Abrahams noted that the payment arrangement "helps set the stage for [AVXS-101] and other gene therapies," adding "we note this strategy is in distinct contrast to what had taken place with other one-time treatments as in [hepatitis C], and believe that this more proactive approach is more likely to ensure the buy-in of key constituents."
Abrahams suggested that the FDA could grant accelerated approval of AveXis' drug.
To read more NewsPoints articles, click here.